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Summary
Background The eﬀ ects of antiretroviral therapy on risk of severe bacterial infections in people with high CD4 cell 
counts have not been well described. In this study, we aimed to quantify the eﬀ ects of immediate versus deferred ART 
on the risk of severe bacterial infection in people with high CD4 cell counts in a preplanned analysis of the START trial. 
Methods The START trial was a randomised controlled trial in ART-naive HIV-positive patients with CD4 cell count 
of more than 500 cells per μL assigned to immediate ART or deferral until their CD4 cell counts were lower than 
350 cells per μL. We used Cox proportional hazards regression to model time to severe bacterial infection, which was 
deﬁ ned as a composite endpoint of bacterial pneumonia (conﬁ rmed by the endpoint review committee), pulmonary 
or extrapulmonary tuberculosis, or any bacterial infectious disorder of grade 4 severity, that required unscheduled 
hospital admissions, or caused death. This study is registered with ClinicalTrials.gov, number NCT00867048.
Findings Patients were recruited from April 15, 2009, to Dec 23, 2013. The data cutoﬀ  for follow-up was May 26, 2015. 
Of 4685 HIV-positive people enrolled, 120 had severe bacterial infections (immediate-initiation group n=34, deferred-
initiation group n=86; median 2·8 years of follow-up). Immediate ART was associated with a reduced risk of severe 
bacterial infection compared with deferred ART (hazard ratio [HR] 0·39, 95% CI 0·26–0·57, p<0·0001). In the 
immediate-initiation group, average neutrophil count over follow-up was 321 cells per μL higher, and average CD4 cell 
count 194 cells per μL higher than the deferred-initiation group (p<0·0001). In univariable analysis, higher time-
updated CD4 cell count (0·78, 0·71–0·85, p=0·0001) was associated with reduced risk of severe bacterial infection. 
Time-updated neutrophil count was not associated with severe bacterial infection. After adjustment for time-updated 
factors in multivariable analysis, particularly the CD4 cell count, the HR for immediate-initiation group moved closer 
to 1 (HR 0·84, 0·50–1·41, p=0·52). These results were consistent when subgroups of the severe bacterial infection 
composite were analysed separately.
Interpretation Immediate ART reduces the risk of several severe bacterial infections in HIV-positive people with 
high CD4 cell count. This is partly explained by ART-induced increases in CD4 cell count, but not by increases in 
neutrophil count.
Funding National Institute of Allergy and Infectious Diseases National Institutes of Health, Agence Nationale de 
Recherches sur le SIDA et les Hépatites Virales, Bundesministerium für Bildung und Forschung, European AIDS 
Treatment Network, Australian National Health and Medical Research Council, UK National Institute for Health 
Research and Medical Research Council, Danish National Research Foundation. 
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license.
Introduction
The Strategic Timing of AntiRetroviral Treatment (START) 
trial, in people with CD4 counts of more than 500 cells per 
μL and who were naive to antiretroviral therapy (ART), 
revealed a 57% reduction in risk of AIDS and non-AIDS 
morbidity and mortality in participants randomly assigned 
to immediate ART initiation compared with those allocated 
to deferred initiation.1 HIV treatment guidelines were 
subsequently rewritten to recommend that people living 
with HIV should be oﬀ ered ART at any CD4 cell count.1–4 
The primary article for the START study reported a 
reduced risk of bacterial infectious disorder events and 
incidence of tuberculosis in the immediate-initiation 
group. Characterisation of the eﬀ ect of early ART on the 
incidence of bacterial infections is important because 
these events are common in people living with HIV.5–10
In the START study, most serious AIDS-related events, 
serious non-AIDS-related events, or deaths occurred in 
patients with CD4 counts above 500 cells per μL and the 
treatment eﬀ ect was only partly mediated by changes in 
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CD4 cell count during follow-up.1 This ﬁ nding suggests 
that ART has beneﬁ cial eﬀ ects on the immune system 
beyond those measured with CD4 cell count. Neutrophils 
play a key part in the innate immune response to bacterial 
infection.11 Known as the hallmark of inﬂ ammation, 
neutrophils are the ﬁ rst of the white blood cells to migrate 
towards a site of bacterial infection to begin killing the 
invading microbes.12 Neutrophils recruit and activate 
monocytes, dendritic cells, and lymphocytes13,14 and are 
also responsible for conﬁ ning the pathogen to the local 
site, thus preventing systemic spread of bacterial disease.15 
We therefore hypothesised that ART increases the number 
of neutrophils, which might mediate the association 
between ART and reduced risk of severe bacterial 
infection. We also aimed to characterise the factors 
associated with risk of severe bacterial infection in this 
multiregional study of people with high CD4 cell counts.
In this Article, we report the eﬀ ects of immediate ART 
on all severe bacterial infections. Our aim was to 
investigate whether the reduction in severe bacterial 
infection observed in the immediate-initiation group 
could be explained by possible increases in neutrophil 
counts, and the increases in CD4 cell counts that were 
observed in this group (as reported previously1), and to 
investigate other factors associated with the incidence of 
severe bacterial infection. The analysis of the eﬀ ect of 
treatment group on incidence of severe bacterial infection 
as a secondary outcome was preplanned, but the choice 
of the composite deﬁ nition of severe bacterial infection 
and the analysis of the extent to which the eﬀ ect might be 
mediated by changes in biomarkers was not preplanned.
Methods
Study design and participants
The START study was a multicontinental, randomised 
trial designed to investigate the risks and beneﬁ ts of 
immediate initiation of ART in asymptomatic HIV-
positive people. Participants with CD4 cell counts above 
500 cells per μL were randomly assigned either to start 
ART immediately or to defer ART until their CD4 cell 
counts dropped to 350 cells per μL, or until the 
development of an AIDS-deﬁ ning event or another 
condition (eg, pregnancy) that required treatment with 
ART. Enrolment began on April 15, 2009, and ended on 
Dec 23, 2013. 4685 HIV-positive people were enrolled 
(immediate-initiation group, n=2326; deferred-initiation 
group, n=2359) at 215 clinical sites caring for people 
living with HIV in 35 countries (the full list of countries 
has been reported previously1). On May 15, 2015, the data 
safety monitoring board concluded that the primary 
outcome in START had been achieved.1 The data cutoﬀ  
for follow-up was May 26, 2015. 
The study was approved by the institutional review 
board or ethics committee at each participating site, and 
written informed consent was obtained from all patients.1 
Procedures
People were followed up 1 month and 4 months after 
randomisation and every 4 months thereafter for data 
collection and routine follow-up clinical evaluation. Total 
follow-up time was about 14 060 person-years, with a 
mean follow-up time of 3·0 years.1 Details of the design 
and data collection methods of the START study have 
been published elsewhere.1,16 CD4 cell count and HIV 
RNA were measured at randomisation, at 1 month and 
4 months after randomisation, and every 4 months 
thereafter; all other laboratory markers were measured at 
randomisation and annually thereafter. A severe bacterial 
infection consisted of any of bacterial pneumonia, 
pulmonary or extrapulmonary tuberculosis (as reviewed 
by the INSIGHT endpoint review committee and 
conﬁ rmed or designated as probable), or any bacterial 
infectious disorder (as reported previously1) that met at 
least one of the three criteria: grade 4 severity, requiring 
unscheduled hospital admission, or causing death. 
Follow-up was censored at the time of the severe bacterial 
infection event, the date of the last study visit, the date of 
death, or the withdrawal date for participants who 
withdrew from the study (censoring date for the analysis). 
The trial protocol has been published previously.1
Research in context
Evidence before this study
We searched the Web of Knowledge for search terms “randomi*” 
AND “trial” AND “antiretroviral” AND “bacter*” AND 
“infection*”, AND “HIV*” on April 1, 2016, for articles published 
in English only. We found no substantive randomised trial 
evidence published about the eﬀ ect of antiretroviral therapy 
(ART) on risk of severe bacterial infections in people with HIV 
and high CD4 cell count (>500 cells per μL) before this study.
Added value of this study
The START trial was a trial of immediate versus deferred ART in 
4685 participants with HIV and high CD4 cell count who were 
followed up for a median of 2·8 years. Our results show that 
ART has a substantial beneﬁ cial eﬀ ect on bacterial infections, 
which is largely mediated by improvements in CD4 cell count in 
people on ART. This beneﬁ t was found also for non-tuberculosis 
bacterial infections. Although there were improvements in 
neutrophil count in the immediate ART group compared with 
the deferred ART arm, time-updated neutrophil count did not 
predict the risk of bacterial infections.
Implications of all the available evidence
ART has a protective eﬀ ect in reducing the risk of a broad 
spectrum of severe bacterial infections in people with HIV, even in 
people with high CD4 cell count. This ﬁ nding further emphasises 
the beneﬁ ts of ART even in people with high CD4 cell count.
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Statistical analysis
We calculated summary statistics of baseline and time-
updated characteristics for all participants. We calculated 
time-updated summary statistics by taking the mean 
value of the characteristic for each person over the 
observed follow-up period (until the censoring date) and 
summarising the mean of all individuals. 
We plotted the change in neutrophil count, total 
lymphocyte count, haemoglobin concentration, platelet 
count, albumin concentration, and CD4 cell count over 
time at annual timepoints, on the basis of values taken 
at annual visits. We ﬁ tted a longitudinal mixed model 
with PROC MIXED in SAS (version 9.4) to assess the 
diﬀ erence in the mean change in laboratory markers 
from study entry between the treatment groups. We 
ﬁ tted a separate mixed model for each of the laboratory 
markers with change since study entry as the dependent 
variable. We adjusted models for the baseline value of 
the laboratory marker and the visit number. A variance 
components covariance structure was speciﬁ ed to 
model the potential correlation between repeated 
laboratory measures collected at diﬀ erent visits for the 
same person. 
We used Cox proportional hazards regression to model 
the time to severe bacterial infection. We estimated 
univariable and multivariable hazard ratios (HRs) with 
95% CIs to assess the association between severe 
bacterial infection and several covariates.
Baseline categorical covariates investigated include treat-
ment group (immediate-initiation, deferred-initiation), 
sex, mode of HIV acquisition (men who have sex with 
men; sex with person of the opposite sex; injection drug 
use, blood products, other, or unknown) and race or 
ethnicity (Asian, black, white, Latino or Hispanic, other). 
Time-updated categorical covariates investigated include 
body-mass index (BMI; <18·5 kg/m², 18·5–24·9 kg/m², 
25·0–34·9 kg/m², ≥35 kg/m²), and smoking status. 
Baseline continuous covariates investigated were age and 
time since HIV diagnosis. Time-updated continuous 
covariates investigated include CD4 cell count, HIV RNA 
viral load (log10), neutrophil count, total lymphocyte count, 
haemoglobin concentration, platelet count, and albumin 
concentration. We stratiﬁ ed all models by a six-category 
variable describing the geographic region of residence 
(Africa, Asia, Australia, Europe and Israel, North America, 
South America and Mexico). We assessed whether the 
eﬀ ect of treatment group was consistent across several 
predeﬁ ned subgroups that were deﬁ ned according to 
characteristics at study entry, by including terms for 
interactions between treatment and subgroup variables in 
expanded Cox models. We also assessed the proportional 
hazards assumption for the treatment eﬀ ect by ﬁ tting the 
interaction with log time.
We did several additional analyses to separately analyse 
some components of the severe bacterial infection 
endpoint where numbers were suﬃ  cient. Analyses were 
done with SAS software (version 9.4). All tests of 
signiﬁ cance were two-sided and used p<0·05 as the 
threshold of statistical signiﬁ cance. The START trial was 
registered with ClinicalTrials.gov, number NCT00867048.
Role of the funding source
The funder had a role in study design and interpretation 
of data and the writing of the report through the 
membership of KLK (Medical Oﬃ  cer HIV Research 
Branch, DAIDS) in the Writing Committee. The funder 
Participants who had a 
severe bacterial infection 
(n=120)
All participants 
(n=4685)
Treatment group
Immediate-initiation 34 (28%) 2326 (50%)
Deferred-initiation 86 (72%) 2359 (50%)
Age (years) 38 (29–47) 36 (29–44)
Female sex 34 (28%) 1257 (27%)
Race or ethnicity
Black 42 (35%) 1410 (30%)
White 61 (51%) 2086 (45%)
Asian, Latino, Hispanic, or other 17 (14%) 1189 (25%)
Geographic region of residence
Africa 27 (23%) 1000 (21%)
Asia 7 (6%) 356 (8%)
Australia 10 (8%) 109 (2%)
Europe and Israel 44 (37%) 1539 (33%)
North America 17 (14%) 507 (11%)
South America 15 (13%) 1174 (25%)
Route of infection with HIV
Men having sex with men 61 (51%) 2586 (55%)
Sex with person of opposite sex 48 (40%) 1790 (38%)
Injection drug use, blood products, other, or 
unknown
11 (9%) 309 (7%)
Time since HIV diagnosis (years) 1·1 (0·4–3·4) 1·0 (0·4–3·1)
Hepatitis B-positive 2 (2%) 128 (3%)
Hepatitis C-positive 9 (8%) 171 (4%)
Time-updated characteristics*†
BMI (kg/m²) 24·1 (21·8–29·7) 24·7 (22·2–27·9)
Current smoker 46 (38%) 1334 (28%)
CD4 cell count (cells per μL) 598 (514–707) 695 (569–837)
HIV RNA (log10 copies per mL) 3·8 (2·6–4·5) 2·4 (1·8–3·7)
Neutrophil count (cells per μL) 2639 (2061–3700) 2960 (2300–3770)
Total lymphocyte count (cells per μL) 2200 (1782–2670) 2165 (1841–2560)
Haemoglobin (g/dL) 14·1 (13·0–15·1) 14·5 (13·4–15·3)
Platelet count (cells per μL × 10³) 240 (196–273) 237 (202–277)
Albumin (g/dL) 4·3 (4·0–4·5) 4·4 (4·2–4·6)
Data are n (%) or median (IQR). BMI=body-mass index. *Summary statistics were calculated for numerical 
time-updated covariates by taking the mean value of the covariate for each person over follow-up and then 
summarising the mean of all individuals. For those with a severe bacterial infection event, the most recent value 
before the event is given. †For covariates presented as time-updated characteristics, the baseline values for all 
participants (n [%] or median [IQR]) were BMI 24·55 kg/m³ (22·1–27·9), current smoker 1496 (32%), CD4 cell count 
651 cells per μL (583–764), HIV RNA 4·1 log10 copies per mL (2·8–4·6), neutrophil count 2830 cells per μL 
(2149–3700), total lymphocyte count 2200 cells per μL (1830–2659), haemoglobin 14·5 g/dL (13·4–15·3), platelet 
count 231 × 10³ cells per μL (195–273), albumin 4·4 (4·1–4·6). 
Table 1: Patient characteristics 
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had no role in the decision to submit the paper for 
publication. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication.
Results
4685 HIV-positive START participants enrolled between 
April 15, 2009, and Dec 23, 2013, were included in the 
analyses. Most participants were male, of white ethnicity, 
with same-sex mode of HIV acquisition, living in the 
region of Europe and Israel, and were non-smokers 
(table 1). 
120 people had at least one severe bacterial infection 
(immediate-initiation group n=34, deferred-initiation 
group n=86; table 2) during 13 854 person-years at risk 
(incidence of 0·87 per 100 person-years of follow-up, 
95% CI 0·71–1·02). By geographic region, the incidence 
of severe bacterial infection was 1·1 per 100 person-years 
(27 in 2429 person-years) in Africa; 0·7 per 100 person-
years (seven in 976 person-years) in Asia; 2·8 per 
100 person-years (ten in 356 person-years) in Australia; 
0·9 per 100 person-years (44 in 5109 person-years) in 
Europe and Israel; 1·0 per 100 person-years (17 in 
1671 person-years) in North America; and 0·5 per 
100 person-years (15 in 3313 person-years) in 
South America. In a univariable Cox model, compared 
with South America, the hazard ratio for severe bacterial 
infection was 2·44 (95% CI 1·30–4·60, p=0·006) in 
Africa, 1·57 (0·64–3·86, p=0·32) in Asia, 1·92 (1·07–3·45, 
p=0·03) in Europe and Israel, 2·18 (1·08–4·41, p=0·03) 
in North America, and 6·19 (2·77–13·79, p<0·0001) in 
Australia. Subsequent Cox models were stratiﬁ ed by 
geographic region.
Baseline median values of biomarkers investigated for 
their association with severe bacterial infection were: 
CD4 count 651 cells per μL (IQR 584–764); neutrophil 
count 2830 cells per μL (2149–3700); total lymphocyte 
count 2200 cells per μL (1830–2659); haemoglobin 
concentration 14·5 g/dL (13·4–15·3); platelet count 
231 × 10³ cells per μL (195 × 10³ to 273 × 10³); and albumin 
concentration 4·4 g/dL (4·1–4·6). During follow-up, the 
change in biomarker values since study entry was 
signiﬁ cantly higher in the immediate-initiation group 
than in the deferred-initiation group, for all biomarkers 
investigated (ﬁ gure 1).
In univariable analysis, immediate initiation of ART 
was associated with a reduced risk of severe bacterial 
infection (HR 0·39, 95% CI 0·26–0·57, p<0·0001; no 
evidence of lack of proportionality in hazards, p=0·97; 
ﬁ gure 2). 43 severe bacterial infection events occurred 
before ART initiation (41 of which occurred in the 
deferred-initiation group) in 5195 person-years at risk 
(incidence of 0·79 per 100 person-years of follow-up) and 
77 occurred after ART initiation (45 of which occurred in 
the deferred-initiation group) in 8659 person-years at risk 
(incidence of 0·89 per 100 person-years of follow-up).
Of 120 people who developed a severe bacterial infection, 
50 had a bacterial infectious disorder (immediate-initiation 
group n=14, deferred-initiation group n=36), 48 developed 
bacterial pneumonia (immediate-initiation group n=14, 
deferred-initiation group n=34), and 26 developed 
tuberculosis (immediate-initiation group n=6, deferred-
initiation group n=20; table 2). These components of 
severe bacterial infection do not total 120 because some 
people had more than one condition.
Univariable and multivariable HRs for a selection of 
factors that were included in the Cox model are presented 
in ﬁ gure 2. In multivariable analysis (after adjustment 
for all covariates listed in the methods including time-
updated variables), the HR (immediate-initiation vs 
deferred-initiation) was no longer signiﬁ cantly below 1 
(multivariable HR 0·84, 95% CI 0·50–1·41, p=0·52; 
univariable 0·39; 0·26–0·57, p<0·0001). 
In multivariable analysis, a BMI above 35 kg/m² was 
associated with an increased risk of severe bacterial 
Immediate-initiation 
group (n=34)
Deferred-initiation 
group (n=86)
Arthritis bacterial 0 2
Bacterial pneumonia 
(reviewed by ERC)
14 34*
Bacterial pyelonephritis 1 0
Campylobacter 
gastroenteritis
1 2
Cellulitis 1 4
Cellulitis staphylococcal 0 1
Endocarditis bacterial 0 1
Erysipelas 2 3
Escherichia urinary tract 
infection
1 1
Furuncle 0 1
Gastroenteritis bacterial 0 1
Gastroenteritis salmonella 1 0
Gastroenteritis Shigella 1 2
Meningitis streptococcal 0 1
Pneumococcal bacteraemia 0 1
Shigella infection 1 1
Staphylococcal abscess 0 2
Streptococcal bacteraemia 1 0
Streptococcal sepsis 0 1
Syphilis outside CNS 1 7
Syphilis in CNS 1 4
Tonsillitis streptococcal 1 0
Tuberculosis (pulmonary) 6 17
Tuberculosis 
(extra-pulmonary)
0 3
Typhoid fever 1 1
Total 34 90*
Infections are listed as MedDRA preferred terms. ERC=INSIGHT endpoint review 
committee. *Four people had both an ERC review bacterial pneumonia and a 
bacterial infectious disorder that satisﬁ ed one of the following three criteria: 
grade 4, hospital admission, or death. 
Table 2: Severe bacterial infection events
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infection when compared with a reference group of a 
BMI between 18·5 and 24·9 kg/m² (HR 2·17, 
95% CI 1·19–3·95, p<0·0001). Higher time-updated 
CD4 cell count was associated with a reduced risk of 
severe bacterial infection (0·78, 0·71–0·85, p=0·0001). 
The time-updated CD4 cell count remained strongly 
associated with a reduced risk of severe bacterial infection 
(0·84, 0·76–0·93, p=0·0006) when time-updated values 
were delayed by 6 months. Adjustment for time-updated 
CD4 cell count in the multivariable model was 
responsible for the attenuation of the HR for treatment 
group. Time-updated neutrophil count was not associated 
with risk of severe bacterial infection (HR [multivariable 
model] 1·00, 95% CI 0·88–1·14, p=0·98); which was also 
the case when neutrophil count was ﬁ tted as a categorical 
variable. Other factors that were included in the 
multivariable model, but were not associated with severe 
bacterial infection, were age (p=0·44), sex (p=0·07; trend 
towards females having lower risk), race/ethnicity 
(p=0·22), time-updated smoking status (p=0·09; trend 
Figure 1: Change in laboratory markers during the study period 
Longitudinal mixed model adjusted for baseline value of biomarker and visit number. Estimated diﬀ erence in CD4 count 194·2 cells per μL (95% CI 185·1–203·3; 
p<0·0001); neutrophil count 321·4 cells per μL (258·6–384·2; p<0·0001); total lymphocyte count 55·3 cells per μL (23·3–87·3; p=0·0007); haemoglobin 0·19 g/dL 
(0·14–0·24; p<0·0001); platelets 17·8 cells per μL × 10³ (15·3–20·2; p<0·0001); albumin 0·09 g/dL (0·07–0·10; p<0·0001).
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towards smokers having higher risk), mode of HIV 
infection (p=0·88), time since HIV diagnosis (p=0·89), 
hepatitis B (p=0·67) and hepatitis C status (p=0·43), 
time-updated HIV RNA viral load (p=0·07; trend towards 
higher levels being associated with higher risk), 
time-updated total lymphocyte count (p=0·10), time-
updated haemoglobin concentration (p=0·20), time-
updated platelet count (p=0·70), and time-updated 
albumin concentration (p=0·11). The tests for interaction 
between the treatment group and several predeﬁ ned 
subgroups that were determined by characteristics upon 
study entry were non-signiﬁ cant.
Given that the beneﬁ cial eﬀ ect of immediate ART on 
risk of severe bacterial infection seems to be partly 
mediated by induced rises in CD4 cell count, we 
considered whether the eﬀ ect would be lower in people 
with baseline CD4 cell counts above the median of 
651 cells per μL than people with baseline CD4 cell 
counts below the median, but the univariable eﬀ ect of 
immediate ART was similar to the overall eﬀ ect (HR 0·43; 
95% CI 0·24–0·80, p=0·007).
We did four sensitivity analyses to explore how 
sensitive the results of our study were to variations in 
the deﬁ nition of severe bacterial infection. In one 
analysis, we excluded tuberculosis from the deﬁ nition of 
severe bacterial infection (appendix p 2). In a second 
analysis, additionally, all syphilis events were ignored 
and follow-up for people who experienced a syphilis 
event was censored at the last visit date, death, or 
withdrawal (appendix p 4). Two further sensitivity 
analyses were done in which bacterial pneumonia and 
bacterial infectious disorder were treated as separate 
endpoints. Results of all these analyses are broadly 
similar to the primary analysis whereby adjustment for 
time-updated CD4 cell count reduces the HR for 
treatment group, and high CD4 cell count predicted 
these endpoints. High BMI was more strongly associated 
with excess risk of bacterial pneumonia than with 
bacterial infectious disorders (appendix p 6). 
Discussion
Immediate ART initiation reduced the risk of severe 
bacterial infections in asymptomatic HIV-positive people 
with high CD4 cell counts by 61%. The beneﬁ t of 
immediate ART was attenuated in statistical models after 
adjustment for time-updated CD4 cell count, suggesting 
that the eﬀ ect of immediate ART is partly mediated by 
the increase in CD4 cell count in the immediate ART 
group and hence this increase in itself or some linked 
immunological pathway is an important mechanism by 
which ART reduces risk of severe bacterial infections. By 
contrast, we found no evidence that the eﬀ ect was 
mediated by the increases seen in neutrophil count with 
early ART, as we initially hypothesised. 
Our ﬁ ndings are consistent with those from previous 
studies, which show the eﬃ  cacy of early ART in 
reducing the risk of bacterial diseases.8,10 In a randomised 
controlled trial that compared immediate initiation of 
Figure 2: Factors associated with severe bacterial infection 
Number of events by treatment group for BMI: BMI lower than 18·5 kg/m² (one immediate vs two deferred), BMI 18·5–24·9 kg/m²(51 immediate vs 17 deferred), 
BMI 25·0–34·9 kg/m² (20 immediate vs 11 deferred), and BMI 25·0 kg/m² or higher (14 immediate vs 4 deferred). All models were stratiﬁ ed by a six-category variable 
describing the geographic region of residence (Africa, Asia, Australia, Europe and Israel, North America, South America and Mexico). Analyses of various subcategories 
of the composite endpoint are presented in the appendix (pp 2–9) and generated broadly consistent results. *Time-updated covariate. †Multivariable model also 
includes age (p=0·44), sex (p=0·07; trend towards women having lower risk than men), race or ethnicity (p=0·22), smoking status (p=0·09; trend towards smokers 
having higher risk than non-smokers), mode of HIV infection (p=0·88), time since diagnosis (p=0·89), hepatitis B (p=0·67), and hepatitis C status (p=0·43). ‡p value 
from likelihood ratio test. 
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ART with deferred ART (according to the most recent 
WHO criteria, which changed during the course of the 
study) in HIV-positive people with CD4 cell count greater 
than 200 cells per μL in Côte d’Ivoire, early ART was 
associated with a 77% reduced risk of invasive bacterial 
disease.8 Another randomised controlled trial, done in 
Haiti in 2010, compared early ART (initiation of ART 
within 2 weeks of enrolment into the study) in people 
with CD4 counts greater than 200 cells per μL and less 
than 350 cells per μL, with no history of an AIDS-deﬁ ning 
illness. The study used the 2010 WHO criteria for 
starting treatment, which involved initiation of ART at a 
CD4 count less than 200 cells per μL or after development 
of an AIDS-deﬁ ning event.10 Early ART in this study was 
associated with a 75% reduced risk of death, where ten of 
29 deaths that occurred during the study were caused by 
a bacterial infection. Neither trial reported on analyses 
describing the extent to which the eﬀ ect on bacterial 
infections was mediated by changes in CD4 cell count or 
neutrophil count.
In accordance with other studies,17–22 we found an 
increased risk of severe bacterial infection, particularly 
for bacterial pneumonia, in people who were obese, and 
by contrast with other studies,20,21 we did not ﬁ nd an 
increased risk of severe bacterial infection in people 
who were underweight. In our study, we investigated the 
eﬀ ect of adjusting our model for time-updated diabetes 
to establish whether BMI was acting as a proxy for excess 
risk of diabetes. We found that diabetes did not attenuate 
the HR for BMI. 
The relationship between BMI and risk of bacterial 
pneumonia was investigated in a 2013 meta-analysis,22 
which concluded that the relationship between BMI 
and pneumonia in the 25 studies included in the meta-
analysis was signiﬁ cantly heterogeneous (p<0·0001). 
Results of the meta-analysis showed a J-shaped 
relationship between BMI and community-acquired 
pneumonia, in which people who were underweight 
had an 80% increased risk of community-acquired 
pneumonia, being overweight was found to be protective 
of community-acquired pneumonia, and people who 
were obese had a 3% increased, but non-signiﬁ cant, risk 
of community-acquired pneumonia.22 
Our ﬁ ndings provide further evidence of a clinical 
beneﬁ t of early initiation of ART. Biomarkers in 
untreated HIV infection tend to decline even in people 
with high CD4 cell counts (ﬁ gure 1). Control of viral 
replication with ART, with consequent beneﬁ ts on 
immunological function, at early stages of HIV infection 
reverses these trends and is important for the prevention 
of a range of bacterial infections. The beneﬁ ts of 
immediate ART were consistent across diﬀ erent 
subgroups and this beneﬁ cial eﬀ ect of early ART did not 
diﬀ er according to age, sex, race or ethnicity, BMI, 
smoking status, CD4 cell count, or time since HIV 
diagnosis. Early ART provides public health beneﬁ ts by 
way of a reduced risk of transmission;23,24 in this study we 
For the Medical Dictionary for 
Regulatory Activities see 
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show individual-level health beneﬁ ts in addition to 
those presented in the START primary publication. Our 
ﬁ ndings could be of particular importance in regions 
where a high burden of bacterial diseases might 
exacerbate the natural history of HIV disease.25–31 
The main strengths of our study are the comparison 
of randomised groups, the use of pre-established 
standardised methods for data collection, and the size 
and diversity of the study cohort. All serious events and 
deaths were reviewed by an endpoint review committee, 
who were blind to the treatment group, using pre-
established INSIGHT criteria.32 Endpoints including 
death from any cause, grade 4 events, and unscheduled 
hospital admis sions for reasons other than AIDS were 
collected and categorised according to codes used in the 
Medical Dictionary for Regulatory Activities (version 18.0). 
Additionally, collation of longitudinal follow-up data 
from 35 countries with standardised data collection 
methods provided a large, ethnically, geographically, 
and socially diverse cohort of HIV-positive people. 
Furthermore, rich data collection allowed for adjustment 
of several participant and HIV-related covariates that 
enabled us to assess potential association of these 
covariates with severe bacterial infection.
One limitation of this study is that only the bacterial 
pneumonia and tuberculosis components of our 
endpoint were reported to and reviewed by the endpoints 
review committee. Other bacterial infections were 
identiﬁ ed only if they were classiﬁ ed as grade 4 events 
and required unscheduled hospital admission or led to 
death. Extrapolation of our ﬁ ndings to less severe 
bacterial infections, for which data were absent, should 
be done with caution. Furthermore, hospital admission 
might be more likely in some settings than others for a 
given infection. Indeed, the incidence of severe bacterial 
infections was notably highest in Australia whereas 
we might have expected higher rates in Africa, 
South America, and Asia. Furthermore, our analyses 
involved few events (n=120), which limits the study 
power. Additionally, although CD4 cell count and HIV 
RNA were measured more frequently, all other laboratory 
markers were measured at randomisation and annually 
thereafter. Therefore, for severe bacterial infection events 
that occurred in the ﬁ rst year after randomisation (n=37; 
eight in immediate ART group and 29 in the deferred 
ART arm), there would be no follow-up measurement of 
these laboratory markers. This might have resulted in 
overestimation of the importance of CD4 cell count in 
explaining the treatment eﬀ ect, relative to the other 
laboratory markers.
In summary, the results of our study show the 
protective eﬀ ect of immediate ART in reducing the risk 
of a broad spectrum of severe bacterial infections in HIV-
positive people. The eﬀ ect of immediate ART appears to 
be mediated in part by ART-induced increases in CD4 cell 
count, but not by the ART-induced increases in 
neutrophil count.
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